Impact of PrEP drugs on HIV prevention and women's reproductive health
Official title: Effects of PrEP Drugs on Female Genital HIV Infection and Women's Reproductive Health
Funded at J. David Gladstone Institutes · NIH-10703238 · Data updated 2026-11-12
This study is looking at how PrEP medications can help prevent HIV in young women and whether they affect women's reproductive health, including fertility and pregnancy, by examining how different factors in the body might change how well these medications work.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | J. David Gladstone Institutes NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | September 14, 2022 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $126,630 |
| NIH project number | 5K99HD110319-02 |
| Project ID | NIH-10703238 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are young women of reproductive age who are at risk of HIV infection.
✕Less likely to help
Patients who are not at risk of HIV or those who are not of reproductive age may not benefit from this research.
What this research studies
This research investigates how pre-exposure prophylactic (PrEP) drugs affect HIV transmission and women's reproductive health, particularly focusing on young women at risk of HIV. It aims to understand the biological and anatomical differences in the female reproductive tract that may influence PrEP efficacy. The study will explore how factors like inflammation and the presence of semen can impact both HIV infection rates and the effectiveness of PrEP. Additionally, it will assess whether PrEP drugs have any adverse effects on fertility and pregnancy processes.
Why it matters
Potential benefit: If successful, this research could lead to improved PrEP strategies that enhance HIV prevention and support women's reproductive health.
How similar studies have gone: While PrEP has been effective in preventing HIV in men, this research addresses a less explored area regarding its impact on women, making it a novel investigation.
Where this research is happening
-
J. David Gladstone Institutes
San Francisco, United States Active
Researchers
- Principal investigator: George, Ashley F — J. David Gladstone Institutes
- Study coordinator: George, Ashley F
Related research
Other NIH-funded projects on the same topics.
-
How PrEP Drugs Affect HIV Risk in Women and Reproductive Health
This project looks at how PrEP medicines work for women, and whether they influence pregnancy-related processes in the uterus.
-
How choosing PrEP products could improve HIV protection for young women in Kenya
This project looks at which HIV-prevention options young Kenyan women prefer and how choosing a product affects how well they stay protected.
-
Effectiveness of PrEP product choice for HIV prevention among young Kenyan women seeking reproductive health services
A study tests which PrEP options best help young Kenyan women stay protected against HIV when they access reproductive health services.
-
Mobile health support to boost PrEP and contraception use among young women in Zambia
A mobile health program helps female university students in Zambia learn about and access HIV prevention and contraception.
-
STI testing added to PrEP programs to protect women from HIV
Offering STI testing alongside routine risk screening to see if more women aged 15–39 start and keep using PrEP to prevent HIV.
-
PrEP options for young Kenyan women: improving HIV protection and adherence
This grant tests how different PrEP options for young women in Kenya affect steady HIV protection when they access reproductive health services.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.